Gender-related differences in mycophenolate mofetil-induced gastrointestinal toxicity in rats

Drug Metabolism and Disposition

Volumn 35, Issue 3, 2007, Pages 449-454

  Stern, Stephan T ^a   Tallman, Melanie N ^a   Miles, Kristini K ^b   Ritter, Joseph K ^b   Dupuis, Robert E ^a   Smith, Philip C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID PHENOLIC GLUCURONIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; ENTEROHEPATIC CIRCULATION; FEMALE; GASTROINTESTINAL TOXICITY; GLUCURONIDATION; INTESTINE EPITHELIUM; MALE; MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; WEIGHT REDUCTION;

ANIMALS; BILE; DIARRHEA; FEMALE; GLUCURONIDES; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; KIDNEY; LIVER; MALE; MICROSOMES; MYCOPHENOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; SEX FACTORS;

RATTUS;

EID: 33847403076     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012013     Document Type: Article

References (36)

1. Barbier O, Girard C, Breton R, Belanger A, and Hum DW (2000) N-Glycosylation and residue 96 are involved in the functional properties of UDP-glucuronosyltransferase enzymes. Biochemistry 39:11540- 11552.
2. Basu NK, Kole L, and Owens IS (2003) Evidence for phosphorylation requirement for human bilirubin UDP-glucuronosyltransferase (UGT1A1) activity. Biochem Biophys Res Commun 303:98-104.
3. Behrend M (2001) Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 24:645-663.
4. Bullingham RES, Nichols AJ, and Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429-455.
5. Catania VA, Dannenberg AJ, Luquita MG, Pozzi EJS, Tucker JK, Yang EK, and Mottino AD (1995) Gender-related differences in the amount and functional state of rat liver UDP-glucuronosyltransferase. Biochem Pharmacol 50:509-514.
6. Hawksworth G, Drasar BS, and Hill MJ (1971) Intestinal bacteria and the hydrolysis of glycosidic bonds. J Med Microbiol 4:451-459.
7. Hesselink DA and Gelder TV (2005) Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 78:351-361.
8. Huang YH, Galijatovic A, Nguyen N, Geske D, Beaton D, Green J, Green M, Peters WH, and Tukey RH (2002) Identification and functional characterization of UDP-glucuronosyltransferase UGT1A8*1, UGT1A8*2 and UGT1A8*3. Pharmacogenetics 12:287-297.
9. Johnson DR, Guo GL, and Klaassen CD (2002) Expression of rat Multidrug Resistance Protein 2 (Mrp2) in male and female rats during normal and pregnenolone-16alpha-carbonitrile (PCN)-induced postnatal ontogeny. Toxicology 178:209-219.
10. Kararli TT (1995) Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351-380.
11. Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, and Hirano T (2004) Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 309:1029-1035.
12. Koster AS, Frankhuijzen-Sierevogel AC, and Noordhock J (1985) Distribution of glucuronidation capacity (1-naphthol and morphine) along the rat intestine. Biochem Pharmacol 34:3527-3532.
13. Kuypers DR, Naesens M, Vermeire S, and Vanrenterghem Y (2005) The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 78:351-361.
14. Matsumoto Y, Hof A, Baumlin Y, and Hof RP (2002) Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model. Transplantation 74:1372-1376.
15. Miles KK, Stern ST, Smith PC, Kessler FK, Ali S, and Ritter JK (2005) An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab Dispos 33:1513-1520.
16. Morissette P, Albert C, Busque S, St-Louis G, and Vinet B (2001) In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. Ther Drug Monit 23:520-525.
17. Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, Figg WD, and Sparreboom A (2004) Influence of genetic variants in UGT 1A1 and UGT 1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 8:854-860.
18. Ransom JT (1995) Mechanism of action of mycophenolate mofetil. Ther Drug Monit 17:681-684.
19. Sfakianos J, Coward L, Kirk M, and Barnes S (1997) Intestinal Uptake and Biliary Excretion of the Isoflavone Genistein in Rats. J Nutr 127:1260-1268.
20. Shelby MK, Cherrington NJ, Vansell NR, and Klassen CD (2003) Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos 31:326-333.
21. Shipkova M, Armstrong VW, Weber L, Niedman PD, Wieland E, Hale J, Tonshoff B, and Oellerich M (2002) Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transport recipients. Ther Drug Monit 24:390-399.
22. Shipkova M, Beck H, Voland A, Armstrong VW, Grone HJ, Oellerich M, and Wieland E (2004) Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics 4:2728-2738.
23. Shipkova M, Wieland E, Schutz E, Wiese C, Niedmann PD, Oellerich M, and Armstrong VW (2001) The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 33:1080-1081.
24. Sollinger HW (2004) Mycophenolates in transplantation. Clin Transplant 18:485-492.
25. Sollinger HW, Belzer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS, Klintmalm GB, McDiarmid SV, Roberts J, Rosenthal JT, et al. (1992) RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection. Ann Surg 216:513-518.
26. Sugioka N, Chen S, Hayashida K, Koyama J, Ohta T, Kishimoto H, Yasumura T, and Takeda K (1995) Stability and pharmacokinetic studies of a new immunosuppressant, mycophenolate mofetil (RS-61443), in rats. Biopharm Drug Dispos 16:591-601.
27. Sugioka N, Koyama H, Ohta T, Kishimoto H, Yasumura T, and Takada K (1996) Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. J Pharm Sci 85:335-338.
28. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, and Kamataki T (1996) Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752-3757.
29. Takatsuka H, Iwasaki T, Okamoto T, and Kakishita E (2003) Intestinal graft-versus-host disease: mechanisms and management. Drugs 63:1-15.
30. Tallman MN, Ritter JK, and Smith PC (2005)) Differential rates of glucuronidation for 7-ethyl-10-hydroxy-camptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP- glucuronosyltransferase isoforms. Drug Metab Dispos 33:977-983.
31. Tedesco-Silva H, Bastien MC, Choi L, Felipe C, Campestrini J, Picard F, and Schmouder R (2005) Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenate sodium or mycophenolate mofetil. Tranplant Proc 37:852-855.
32. Van Gelder T, Hilbrands LB, Vanenterghem Y, Weimar W, Fijter D, Squifflet JP, Hene RJ, Verpooten GA, Navarro MT, Hale MD, et al. (1999) A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplant 68:261-266.
33. Vogel A, Ockenga J, Ehmer U, Barut A, Kramer FJ, Tukey RH, Manns MP, and Strassburg CP (2002) Polymorphisms of the carcinogen detoxifying UDP-glucuronosyltransferase UGT 1A7 in proximal digestive tract cancer. Z Gastroenterol 40:497-502.
34. Westley IS, Brogan LR, Morris RG, Evans AM, and Sallustio BC (2006) Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos 34:261-266.
35. Wieland E, Shipkova M, Schellhaas U, Schutz, Niedmann PD, Armstrong VW, and Oellerich M (2000) Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects. Clin Biochem 33:107-113.
36. Wiwattanawongsa K, Heinzen EL, Kemp DC, Dupuis RE, and Smith PC (2001) Determination of mycophenolic acid and its phenol glucuronide metabolite in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 763:35-45.